Christopher B. Benton

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Benton, C.B., Benton, Christopher, C B Benton, C. Benton, Christopher B Benton, Christopher B. Benton, Christopher Benton, Christopher Brent Benton, Christopher B. Benton

124

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Health Science Center at Houston University of California, Irvine Washington University in St. Louis Baylor College of Medicine

About

Christopher B. Benton is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	734
2	Health Sciences	3	3	330
3	Cell Biology	2	2	79
4	Cellular Therapies	1	1	33
5	Emergency Medicine	1	1	41

Christopher B. Benton

Publications

Citations

H-Index

Page 1

	Year	Citations
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton, American Journal of Hematology	2017	429
The crystal structure of human interferon β at 2.2-Å resolution Michael Karpusas, M. Chester Nolte, Christopher B. Benton, Proceedings of the National Academy of Sciences	1997	206
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study Farhad Ravandi, Rita Assi, Naval Daver, The Lancet Haematology Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHigh-risk Myelodysplastic SyndromeHematology	2019	137
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Christopher B. Benton, Blood Advances Mixed-phenotype Acute LeukemiaGeneticsPathologyTp53-mutant MdsMyeloid Neoplasia	2020	125
Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes Hagop M. Kantarjian, Jing Ning, Preetesh Jain, Cancer	2016	120
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial Nicholas J. Short, Hagop M. Kantarjian, Sanam Loghavi, The Lancet Haematology Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHematologyClinical Trials	2018	115
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Blood Advances	2017	108
<i>DDX41</i> mutations in myeloid neoplasms are associated with male gender, <i>TP53</i> mutations and high‐risk disease Andres Quesada, Mark J. Routbort, Courtney D. DiNardo, American Journal of Hematology Hematological MalignancyOncologyCancer PathologyMyeloid NeoplasmsSomatic Variant	2019	104
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial Tapan M. Kadia, Jörge E. Cortes, Farhad Ravandi, The Lancet Haematology Hematological MalignancyElderly PatientsSingle-arm TrialMedicineMixed-phenotype Acute Leukemia	2018	90
Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor Nicholas J. Short, Hagop M. Kantarjian, Koji Sasaki, American Journal of Hematology	2016	55

Page 1